Deep learning model for individualized trajectory prediction of clinical outcomes in mild cognitive impairment

Wonsik Jung1, Si Eun Kim2,3, Jun Pyo Kim2,4,5

  • 1Department of Brain and Cognitive Engineering, Korea University, Seoul, Republic of Korea.

Abstract

Insights

Predicting dementia progression in mild cognitive impairment (MCI) is challenging. A new deep learning model accurately forecasts cognitive decline and MRI changes in MCI patients, aiding early risk identification.

Area of Science:

  • Neuroscience
  • Artificial Intelligence
  • Medical Imaging

Background:

  • Predicting dementia progression in mild cognitive impairment (MCI) is crucial for timely intervention.
  • Current methods often lack individual-level accuracy in forecasting cognitive decline and associated biomarkers.
  • Identifying patients at high risk for rapid progression is a significant clinical challenge.

Purpose of the Study:

  • To develop a deep learning model for predicting individual cognitive decline in MCI patients.
  • To forecast changes in magnetic resonance imaging (MRI) markers over time for MCI individuals.
  • To enhance early identification of MCI patients at risk of progressing to dementia.

Main Methods:

  • Recruited 657 amnestic MCI patients undergoing cognitive, MRI, and amyloid-β (Aβ) positron emission tomography (PET) scans.
  • Developed a novel deep learning architecture using a recurrent neural network with an attention mechanism.
  • Trained the model with demographic, genetic, neuropsychological, MRI, and Aβ PET data.

Main Results:

  • The predictive model achieved strong performance (AUC = 0.814 ± 0.035) in cross-validation.
  • Demonstrated reliable prediction of cognitive decline and MRI marker changes over time.
  • Identified faster cognitive decline and brain atrophy in amyloid-β positive (Aβ+) compared to Aβ- patients.

Conclusions:

  • The developed deep learning model offers an effective and accurate method for predicting MCI progression.
  • The model can assist clinicians in identifying individuals at higher risk of rapid cognitive decline.
  • Further validation and refinement are recommended to enhance clinical decision-making.